Only 8% of new cancer drug authorisations are for children – this needs to improve

The report, From patent to patient – analysing access to innovative cancer drugs, looks at how efficiently new cancer drugs licensed in Europe reach NHS patients here in the UK. The main findings were:

    – Only 8% of new drug authorisations are for children
    – Cancers of unmet need, such as brain, womb, bladder, oesophageal, liver and pancreatic are missing out on advances
    – Leaps forward in cancer research mean many more new drugs
    – Average time from patent to NHS patient increased by more than a year
    – NICE is not doing enough to ensure most innovative treatments reach patients.


    Read all the latest fundraising news, charity news and commentary on childhood cancer.

    Sara Wakeling is a patient advocate on the Cancer Grand Challenge, NexTGen.
    Delighted to be invited as speakers representing the parental perspective of rhabdomyosarcoma.
    Please consider participating in a research interview as part of the REFoRMS (Relapsed and Refractory Rhabdomyosarcoma) study, led by the University of York.